All In Biotech

Drug Trial Radar · NCT04543591

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

Dec 10, 2020

Primary completion

Sep 19, 2025

Study completion Mar 20, 2026

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.

Conditions

  • Thrombotic Microangiopathy

Interventions

  • RavulizumabBiological

    Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

  • PlaceboOther

    Matching placebo

  • Best supportive careOther

    Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment PeriodTime frame: Up to Week 26

Locations

66 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Tampa, Florida

  • Research Site

    Grosse Pointe Farms, Michigan

  • Research Site

    Durham, North Carolina

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Seattle, Washington

  • Research Site

    Parkville, Australia

  • Research Site

    Bruges, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Chênée, Belgium

  • Research Site

    Yvoir, Belgium

  • Research Site

    Cerqueira César, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Jaú, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Suzhou, China

  • Research Site

    Tianjin, China

  • Research Site

    Angers, France

  • Research Site

    La Tronche, France

  • Research Site

    Nice, France

  • Research Site

    Hamburg, Germany

  • Research Site

    Ulm, Germany

  • Research Site

    Athens, Greece

  • Research Site

    Pátrai, Greece

  • Research Site

    Thessaloniki, Greece

  • Research Site

    Halfa, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Roma, Italy

  • Research Site

    Udine, Italy

  • Research Site

    Akita, Japan

  • Research Site

    Anjo, Japan

  • Research Site

    Chiba, Japan

  • Research Site

    Fukushima, Japan

  • Research Site

    Isehara-shi, Japan

  • Research Site

    Kurashiki-shi, Japan

  • Research Site

    Minatoku, Japan

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.